How to buy Acorda Therapeutics stock | $4.65

Acorda Therapeutics Inc is a biotechnology business based in the US. Acorda Therapeutics shares (ACOR) are listed on the NASDAQ and all prices are listed in US Dollars. Acorda Therapeutics employs 167 staff and has a trailing 12-month revenue of around 0.00.

Acorda Therapeutics stock price (NASDAQ: ACOR)

Use our graph to track the performance of ACOR stocks over time.

Acorda Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$4.65
52-week range	$3.27 - $8.66
50-day moving average	$4.46
200-day moving average	$4.28
Wall St. target price	$10.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-14.72

Buy Acorda Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Acorda Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Acorda Therapeutics price performance over time

Historical closes compared with the close of $4.65 from 2021-10-18

1 week (2021-10-11)	3.56%
1 month (2021-09-17)	-1.69%
3 months (2021-07-19)	28.45%
6 months (2021-04-19)	10.45%

1 year (2020-10-19)	573.91%
2 years (2019-10-18)	89.02%
3 years (2018-10-19)	17.86
5 years (2016-10-19)	20.05

Is Acorda Therapeutics under- or over-valued?

Valuing Acorda Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Acorda Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Acorda Therapeutics's PEG ratio

Acorda Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Acorda Therapeutics financials

Revenue TTM	$151.9 million
Gross profit TTM	$96.8 million
Return on assets TTM	-8.1%
Return on equity TTM	-54.85%
Profit margin	-86.91%
Book value	$17.15
Market capitalisation	$52.4 million

TTM: trailing 12 months

Shorting Acorda Therapeutics shares

There are currently 570,372 Acorda Therapeutics shares held short by investors – that's known as Acorda Therapeutics's "short interest". This figure is 24.7% down from 757,862 last month.

There are a few different ways that this level of interest in shorting Acorda Therapeutics shares can be evaluated.

Acorda Therapeutics's "short interest ratio" (SIR)

Acorda Therapeutics's "short interest ratio" (SIR) is the quantity of Acorda Therapeutics shares currently shorted divided by the average quantity of Acorda Therapeutics shares traded daily (recently around 138104.60048426). Acorda Therapeutics's SIR currently stands at 4.13. In other words for every 100,000 Acorda Therapeutics shares traded daily on the market, roughly 4130 shares are currently held short.

However Acorda Therapeutics's short interest can also be evaluated against the total number of Acorda Therapeutics shares, or, against the total number of tradable Acorda Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acorda Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Acorda Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0612% of the tradable shares (for every 100,000 tradable Acorda Therapeutics shares, roughly 61 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acorda Therapeutics.

Find out more about how you can short Acorda Therapeutics stock.

Acorda Therapeutics share dividends

We're not expecting Acorda Therapeutics to pay a dividend over the next 12 months.

Have Acorda Therapeutics's shares ever split?

Acorda Therapeutics's shares were split on a 1:6 basis on 3 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acorda Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Acorda Therapeutics shares which in turn could have impacted Acorda Therapeutics's share price.

Acorda Therapeutics share price volatility

Over the last 12 months, Acorda Therapeutics's shares have ranged in value from as little as $3.27 up to $8.66. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acorda Therapeutics's is 0.5799. This would suggest that Acorda Therapeutics's shares are less volatile than average (for this exchange).

Acorda Therapeutics overview

Acorda Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra.

Frequently asked questions

What percentage of Acorda Therapeutics is owned by insiders or institutions?
Currently 1.626% of Acorda Therapeutics shares are held by insiders and 34.059% by institutions. How many people work for Acorda Therapeutics?
Latest data suggests 167 work at Acorda Therapeutics. When does the fiscal year end for Acorda Therapeutics?
Acorda Therapeutics's fiscal year ends in December. Where is Acorda Therapeutics based?
Acorda Therapeutics's address is: 420 Saw Mill River Road, Ardsley, NY, United States, 10502 What is Acorda Therapeutics's ISIN number?
Acorda Therapeutics's international securities identification number is: US00484M6012 What is Acorda Therapeutics's CUSIP number?
Acorda Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00484M106